

Casirivimab/Imdevimab Infusion Intake/Prescriber Order



Prescriber agrees:

Patient Information

- ✓ I understand this drug is not authorized for use in hospitalized coronavirus disease 2019 (COVID-19) patients, patients requiring oxygen therapy due to COVID-19, patients who require an increase in baseline oxygen flow rate due to COVID-19 and the patient or his/her guardian have provided their informed consent for the administration of Casirivimab/Imdevimab.
- ✓ I understand Casirivimab/Imdevimab should only be used for the treatment of mild to moderate COVID-19 in adults and pediatric patients with positive results of direct SARS-CoV-2 viral testing who are 12 years of age and older weighing at least 40 kg, and who are at high risk for progressing to severe COVID-19 and/or hospitalization, and when the known and potential benefits to patients outweigh the known and potential risks of such product.

Patier	nt Name		Date of Birth		iender] Male Female	
Facilit	у		Room/Bed	Height	V	Veight
Clinical Information						
Date of positive COVID-19 test result			Date of symptom ons	Date of symptom onset and disease manifestation		
Adult Patient meets at least one of the following criteria (Check all that apply)						
☐ Has chronic kidney disease			\square Is currently rec	 ☐ Has immunosuppressive disease ☐ Is currently receiving immunosuppressive treatment ☐ Is ≥65 years of age 		
OR □ Patient is ≥55 years of age AND has □ Cardiovascular disease OR □ Hypertension OR □ Chronic obstructive pulmonary disease/other chronic respiratory disease						
Orders						
 Follow infusion with 0.9 % Sodium Chloride 25 mL to infuse at same rate as infusion to clear administration set of drug post infusion 0.9% Sodium Chloride 10 mL flush PRN Acute infusion reaction orders: PHARMACY TO PROVIDE IN ANAPHYLAXIS E KIT 						
Check	C Drug or Treatment	Severity	Over 30 kg	Route		Note
	Epinephrine 1 mg/mL amp (1:1000)	Moderate to Severe	□ 0.3 mg	□ SQ □ IM	☐ Repeat in	3-5 mins PRN
	Diphenhydramine Oral	Mild	□ 25 mg □ 50 mg	PO		
	Diphenhydramine 50mg/mL vial	Moderate to Severe	□ 25 mg □ 50 mg	Slow IV or IM	☐ Repeat in 3-5 mins PRN MAX dose = 50 mg	
	Methylprednisolone Sodium Succinate 125mg/2mL	Moderate to Severe	125 mg	□ IM □ IV	x1dose	
	Albuterol inhaler	Moderate to Severe	90 mcg/act	INHALER	1-2 puffs PRN	
Facili	ity Nurse to call/fax above informat	ion to physician/LIP I	Fither have physician	/I IP sian below	v or obtain a	s a telephone order
Nurse			Print Name	-		Date
Physician/prescriber			Print Name	Print Name		
Dharn	nacy Name		AX COMPLETED FOR	MTO (``	_